<DOC>
	<DOCNO>NCT01465113</DOCNO>
	<brief_summary>This study conduct determine vitamin D supplementation increase level protein may involve decrease risk esophageal cancer patient Barrett 's esophagus . Subjects Barrett 's esophagus take vitamin D supplementation 2-12 week depend severity condition , receive upper endoscopy procedure vitamin D supplementation trial .</brief_summary>
	<brief_title>Vitamin D Supplementation 15-Prostaglandin Dehydrogenase Expression Barrett 's Esophagus</brief_title>
	<detailed_description>28-day run-in phase subject treat proton pump inhibitor ( omeprazole 20 mg po q day equivalent dose another proton pump inhibitor ) . The purpose run-in phase minimize esophagitis , cause histologic change confuse dysplasia . After run-in phase , subject undergo upper endoscopy Barrett 's surveillance Barrett 's map part routine clinical care . At time endoscopy , research biopsy obtain study . Subjects eligible continue study take vitamin D3 ( Cholecalciferol ) 50,000 IU capsule weekly without daily metformin total two twelve week depend severity Barrett 's esophagus . After completion vitamin D3 subject return EGD ( endoscopy ) biopsies research study .</detailed_description>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Known diagnosis shortsegment longsegment Barrett 's esophagus previously make upper endoscopy show salmoncolored distal esophageal mucosa biopsy reveal intestinal metaplasia goblet cell . Potential study subject may contact mailing phone call may approach clinic . Additionally , potential study subject may approach use webbased recruitment tool . Informed consent obtain research coordinator study investigator . Subjects may take calcium supplement previous history hypercalcemia Subjects may diabetes mellitus Subjects may history prior malignancy except esophageal adenocarcinoma Willing donate 90 mL blood endoscopic mucosal biopsy research The following additional inclusion criterion apply patient Vitamin D/metformin subarm low grade dysplasia/no dysplasia arm : At least 2 cm circumferential Barrett 's esophagus segment length ( C2M2 Prague C &amp; M criterion ) Normal renal function ( defined creatinine within normal institutional limit ) Pregnancy Known chronic liver disease ( Child 's B cirrhosis ) Known chronic kidney disease ( creatinine â‰¥ 3.0 ) Esophageal adenocarcinoma Allergic reaction omeprazole Allergic reaction vitamin D Unable unwilling provide inform consent Known hypercalcemia Previous ablative therapy Barrett 's esophagus Patients stable ( &gt; /=4 week duration ) dose &gt; 2000 IU/day ( equivalent ) vitamin D supplementation The following additional exclusion criterion apply patient Vitamin D/metformin subarm dysplasia/low grade dysplasia arm : Allergic reaction metformin History diabetes mellitus History lactic acidosis History B12 deficiency Participants may use metformin , cimetidine ( Tagamet ) furosemide ( Lasix ) , nifedipine ( Cardizem ) , drug contraindicate use metformin . Treatment oral hypoglycemic agent Participants plan undergo elective radiologic study involve intravascular administration iodinate contrast material . Known chronic kidney disease creatinine great normal institutional limit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Barrett 's Esophagus</keyword>
	<keyword>Vitamin D3</keyword>
	<keyword>cholecalciferol</keyword>
	<keyword>15-Prostaglandin Dehydrogenase Expression</keyword>
	<keyword>metformin</keyword>
</DOC>